{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:10:45Z","timestamp":1781856645626,"version":"3.54.5"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,25]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Human African trypanosomiasis (HAT), or sleeping sickness, continues to be a major threat to human health in 36 countries throughout sub-Saharan Africa with up to 60 million people at risk. Over the last decade, there have been several advances in this area, some of which are discussed in this overview. Due to the concerted efforts of several bodies, including better identification and treatment of cases and improved tsetse fly vector control, the number of cases of HAT has declined dramatically. The clinical heterogeneity of HAT has also been increasingly recognized, and the disease, while usually fatal if untreated or inadequately treated, does not always have a uniformly fatal outcome. Improved methods of HAT diagnosis have now been developed including rapid diagnostic tests. Novel drug treatment of HAT has also been developed, notably nifurtimox\u2013eflornithine combination therapy (NECT) for late-stage Trypanosoma brucei gambiense, oral fexinidazole for early and the early component of the late-stage of T.b. gambiense, and the new oral compounds of the oxaborole group, which have shown considerable promise in field trials. Advances in HAT neuropathogenesis have been steady, though largely incremental, with a particular focus on the role of the blood\u2013brain barrier in parasite entry into the central nervous system and the relevant importance of both innate and adaptive immunity. While the World Health Organization goal of elimination of HAT as a public health problem by 2020 has probably been achieved, it remains to be seen whether the second more ambitious goal of interruption of transmission of HAT by 2030 will be attained.<\/jats:p>","DOI":"10.1093\/qjmed\/hcad273","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T02:53:55Z","timestamp":1702090435000},"page":"391-395","source":"Crossref","is-referenced-by-count":9,"title":["The evolving spectrum of human African trypanosomiasis"],"prefix":"10.1093","volume":"117","author":[{"given":"P G E","family":"Kennedy","sequence":"first","affiliation":[{"name":"School of Psychology and Neuroscience, College of Medical, Veterinary and Life Sciences, University of Glasgow, Wellcome Surgical Institute , Garscube Campus , Glasgow G61 1QH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"2024062520364737200_hcad273-B1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fimmu.2019.00039","article-title":"Clinical and neuropathogenetic aspects of human African trypanosomiasis","volume":"10","author":"Kennedy","year":"2019","journal-title":"Front Immunol"},{"key":"2024062520364737200_hcad273-B2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1474-4422(12)70296-X","article-title":"Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)","volume":"12","author":"Kennedy","year":"2013","journal-title":"Lancet Neurol"},{"key":"2024062520364737200_hcad273-B3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1172\/JCI200421052","article-title":"Human African trypanosomiasis of the CNS: current issues and challenges","volume":"113","author":"Kennedy","year":"2004","journal-title":"J Clin Invest"},{"key":"2024062520364737200_hcad273-B4","doi-asserted-by":"crossref","first-page":"e3349","DOI":"10.1371\/journal.pntd.0003349","article-title":"Human African trypanosomiasis presenting at least 29 years after infection\u2014what can this teach us about the pathogenesis and control of this neglected tropical disease?","volume":"8","author":"Sudarshi","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2024062520364737200_hcad273-B5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ana.21429","article-title":"The continuing problem of human African trypanosomiasis (sleeping sickness)","volume":"64","author":"Kennedy","year":"2008","journal-title":"Ann Neurol"},{"key":"2024062520364737200_hcad273-B6","first-page":"1","year":"1998"},{"key":"2024062520364737200_hcad273-B7","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/S0140-6736(17)31510-6","article-title":"Human African trypanosomiasis","volume":"390","author":"B\u00fcscher","year":"2017","journal-title":"Lancet"},{"key":"2024062520364737200_hcad273-B8"},{"key":"2024062520364737200_hcad273-B9","doi-asserted-by":"crossref","first-page":"e1246","DOI":"10.1371\/journal.pntd.0001246","article-title":"Prevalence of human African trypanosomiasis in the democratic republic of the Congo","volume":"5","author":"Mumba","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"2024062520364737200_hcad273-B10","doi-asserted-by":"crossref","first-page":"e0010885","DOI":"10.1371\/journal.pntd.0010885","article-title":"Human African trypanosomiasis cases diagnosed in non-endemic countries (2011-2020)","volume":"16","author":"Franco","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2024062520364737200_hcad273-B11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.actatropica.2005.08.001","article-title":"Clinical aspects of 2541 patients with second stage human African trypanosomiasis","volume":"97","author":"Blum","year":"2006","journal-title":"Acta Trop"},{"key":"2024062520364737200_hcad273-B12","doi-asserted-by":"crossref","first-page":"e906","DOI":"10.1371\/journal.pntd.0000906","article-title":"Focus specific clinical profiles in human African trypanosomiasis caused by Trypanosoma brucei rhodesiense","volume":"4","author":"MacLean","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"2024062520364737200_hcad273-B13","doi-asserted-by":"crossref","first-page":"e968","DOI":"10.1371\/journal.pntd.0000968","article-title":"Clinical presentation of T.b. rhodesiense sleeping sickness in second stage patients from Tanzania and Uganda","volume":"5","author":"Kuepfer","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"2024062520364737200_hcad273-B14","doi-asserted-by":"crossref","first-page":"e1358","DOI":"10.1371\/journal.pntd.0001358","article-title":"Sleeping sickness in travelers\u2014do they really sleep?","volume":"5","author":"Urech","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"2024062520364737200_hcad273-B15","first-page":"e1691","article-title":"Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal","volume":"73","author":"Camara","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024062520364737200_hcad273-B16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2471\/BLT.23.290173","article-title":"Target product profile: diagnostic test for Trypanosoma brucei rhodesiense","volume":"101","author":"Priotto","year":"2023","journal-title":"Bull World Health Organ"},{"key":"2024062520364737200_hcad273-B17","first-page":"222","volume-title":"The Fatal Sleep","author":"Kennedy","year":"2019","edition":"3rd edn"},{"key":"2024062520364737200_hcad273-B18","doi-asserted-by":"crossref","first-page":"e0004608","DOI":"10.1371\/journal.pntd.0004608","article-title":"Sensitivity and specificity of a prototype rapid diagnostic test for the detection of Trypanosoma brucei gambiense infection: a multi-centric prospective study","volume":"10","author":"Bisser","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2024062520364737200_hcad273-B19","doi-asserted-by":"crossref","first-page":"e0006386","DOI":"10.1371\/journal.pntd.0006386","article-title":"Prospective evaluation of a rapid diagnostic test for Trypanosoma brucei gambiense infection developed using recombinant antigens","volume":"12","author":"Lumbala","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2024062520364737200_hcad273-B20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/trstmh\/trx034","article-title":"The challenging problem of disease staging in human African trypanosomiasis (sleeping sickness): a new approach to a circular question","volume":"111","author":"Njamnshi","year":"2017","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2024062520364737200_hcad273-B21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.actatropica.2004.10.001","article-title":"Sleep structure: a new diagnostic tool for stage determination in sleeping sickness","volume":"93","author":"Buguet","year":"2005","journal-title":"Acta Trop"},{"key":"2024062520364737200_hcad273-B22","doi-asserted-by":"crossref","first-page":"e1525","DOI":"10.1371\/journal.pntd.0001525","article-title":"Actigraphy in human African trypanosomiasis as a tool for objective clinical evaluation and monitoring: a pilot study","volume":"6","author":"Njamnshi","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2024062520364737200_hcad273-B23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"key":"2024062520364737200_hcad273-B24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","article-title":"Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial","volume":"391","author":"Mesu","year":"2017","journal-title":"Lancet"},{"key":"2024062520364737200_hcad273-B25","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S1473-3099(19)30612-7","article-title":"New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice","volume":"20","author":"Lindner","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2024062520364737200_hcad273-B26","doi-asserted-by":"crossref","first-page":"e1665","DOI":"10.1016\/S2214-109X(22)00338-2","article-title":"Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2-3 trial","volume":"10","author":"Kande Betu Kumesu","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2024062520364737200_hcad273-B27","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1473-3099(22)00660-0","article-title":"Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2\/3 trial","volume":"23","author":"Betu Kumeso","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024062520364737200_hcad273-B28","doi-asserted-by":"crossref","first-page":"e1308","DOI":"10.1371\/journal.pntd.0001308","article-title":"Melarsoprol cyclodextrin inclusion complexes as promising oral candidatesfor the treatment of human African trypanosomiasis","volume":"5","author":"Rodgers","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"2024062520364737200_hcad273-B29","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1073\/pnas.94.8.4167","article-title":"A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei","volume":"94","author":"Kennedy","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024062520364737200_hcad273-B30","first-page":"806","article-title":"Kynurenine pathway activation in human African trypanosomiasis","volume":"215","author":"Sternberg","year":"2017","journal-title":"J Infect Dis"},{"key":"2024062520364737200_hcad273-B31","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1645\/GE-287R","article-title":"African trypanosome interactions with an in vitro model of the human blood-brain barrier","volume":"90","author":"Grab","year":"2004","journal-title":"J Parasitol"},{"key":"2024062520364737200_hcad273-B32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4269\/ajtmh.2011.10-0487","article-title":"Magnetic resonance imaging to assess blood-brain barrier damage in murine trypanosomiasis","volume":"84","author":"Rodgers","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2024062520364737200_hcad273-B33","doi-asserted-by":"crossref","first-page":"e0010962","DOI":"10.1371\/journal.pntd.0010962","article-title":"Serial magnetic resonance imaging o fsplenomegaly in the Trypanosoma brucei infected mouse","volume":"16","author":"Paterson","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2024062520364737200_hcad273-B34","doi-asserted-by":"crossref","first-page":"e2384","DOI":"10.1371\/journal.pntd.0002384","article-title":"eCollection 2013. In vivo imaging of trypanosome-brain interactions and development of a rapid screening test for drugs against CNS stage trypanosomiasis","volume":"7","author":"Myburgh","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2024062520364737200_hcad273-B35","doi-asserted-by":"crossref","first-page":"e43913","DOI":"10.1371\/journal.pone.0043913","article-title":"Early invasion of brain parenchyma by African trypanosomes","volume":"7","author":"Frevert","year":"2012","journal-title":"PLoS One"},{"key":"2024062520364737200_hcad273-B36","doi-asserted-by":"crossref","first-page":"e0009892","DOI":"10.1371\/journal.pntd.0009892","article-title":"Microarray profiling predicts early neurological and immune phenotypic traits in advance of CNS disease during disease progression in Trypanosoma. b. brucei infected CD1 mouse brains","volume":"15","author":"Montague","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2024062520364737200_hcad273-B37","doi-asserted-by":"crossref","first-page":"17716","DOI":"10.7554\/eLife.17716","article-title":"The skin is a significant but overlooked anatomical reservoir for vector borne African trypanosomes","volume":"5","author":"Capewell","year":"2016","journal-title":"Elife"},{"key":"2024062520364737200_hcad273-B38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/infdis\/jir734","article-title":"Distinct toll-like receptor signals regulate cerebral parasite load andinterferon alpha\/beta and tumor necrosis factor alpha-dependent T-cell infiltration in the brains of Trypanosoma brucei-infected mice","volume":"205","author":"Amin","year":"2012","journal-title":"J Infect Dis"},{"key":"2024062520364737200_hcad273-B39","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1212\/NXI.0000000000000610","article-title":"Generation of neuroinflammation in human African trypanosomiasis","volume":"6","author":"Rodgers","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["QJM: An International Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/qjmed\/advance-article-pdf\/doi\/10.1093\/qjmed\/hcad273\/54586810\/hcad273.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/article-pdf\/117\/6\/391\/58329978\/hcad273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/article-pdf\/117\/6\/391\/58329978\/hcad273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T20:57:59Z","timestamp":1719349079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/qjmed\/article\/117\/6\/391\/7462774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2024,6,25]]}},"URL":"https:\/\/doi.org\/10.1093\/qjmed\/hcad273","relation":{},"ISSN":["1460-2725","1460-2393"],"issn-type":[{"value":"1460-2725","type":"print"},{"value":"1460-2393","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2023,12,8]]}}}